Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Robin FoàRenato BassanAntonella VitaleLoredana EliaAlfonso PiciocchiMaria-Cristina PuzzoloMartina CanichellaPiera VieroFelicetto FerraraMonia LunghiFrancesco FabbianoMassimiliano BonifacioNicola FracchiollaPaolo Di BartolomeoAlessandra MancinoMaria-Stefania De ProprisMarco VignettiAnna GuariniAlessandro RambaldiSabina Chiarettinull nullPublished in: The New England journal of medicine (2020)
A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.).